MAXIMUM STRENGTH PEPCID AC TABLET

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

FAMOTIDINE

から入手可能:

MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC

ATCコード:

A02BA03

INN（国際名）:

FAMOTIDINE

投薬量:

20MG

医薬品形態:

TABLET

構図:

FAMOTIDINE 20MG

投与経路:

ORAL

パッケージ内のユニット:

5/25

処方タイプ:

OTC

治療領域:

HISTAMINE H2-ANTAGONISTS

製品概要:

Active ingredient group (AIG) number: 0118722001; AHFS:

認証ステータス:

APPROVED

承認日:

2011-12-06

製品の特徴

PRODUCT MONOGRAPH
MAXIMUM STRENGTH PEPCID
®
AC
famotidine tablets
FILM COATED TABLETS 20 MG
Mfr. Std.
HISTAMINE H
2
RECEPTOR ANTAGONIST
McNeil Consumer Healthcare,
division of Johnson & Johnson Inc.
88 McNabb Street
Markham, Ontario
L3R 5L2
Date of Preparation:
Nov 10, 2011
Date of Revision:
May 24, 2019
Submission Control No: 225990
_MAXIMUM STRENGTH PEPCID_
®
_AC _
_ _
_Page 1 of 22_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
.........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
....................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................3
ADVERSE REACTIONS
....................................................................................................5
DRUG INTERACTIONS
....................................................................................................9
DOSAGE AND ADMINISTRATION
................................................................................7
OVERDOSAGE
.................................................................................................................10
ACTION AND CLINICAL PHARMACOLOGY
...............................................................8
STORAGE AND STABILITY
..........................................................................................13
DOSAGE FORMS, COMPOSITION AND PACKAGING
..............................................13
PART II: SCIENTIFIC
INFORMATION................................................................................14
PHARMACEUTICAL INFORMATION
..........................................................................14
CLINICAL TRIALS
........................................................................................